Clinical Trials Logo

Clinical Trial Summary

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is an cerebral microangiopathy secondary to mutations in the NOTCH3 gene located on chromosome 19. This disease is the most frequent of the hereditary vascular leukoencephalopathies.

CADASIL begins between the ages of 20 and 40 with the appearance of hyper-signs of brain white matter visible on T2 sequences in magnetic resonance imaging (MRI). Before the age of 30, patients are most often asymptomatic. The disease is then responsible for different neurological manifestations:

1. Migraine attacks with aura occur on average in one in three patients, most often at the beginning of the course of the disease, sometimes even before the appearance of MRI abnormalities;

2. Transient ischemic strokes or strokes associated with small cerebral infarcts occur most frequently after the age of 50-60 years in more than two out of three patients;

3. Mood disorders are reported by one in three patients in the same age group;

4. Cognitive disorders that affect executive functions, especially after the age of 60, until the stage of severe dementia associated with walking disorders are observed during the course of the disease.

To date, there is no treatment whose efficacy has been proven in CADASIL. Various studies have shown that the accumulation of the most destructive brain tissue lesions at the subcortical level was closely correlated in CADASIL with the clinical severity of patients (motor and cognitive disability). It is now possible to measure microstructural changes in brain tissue in diffusion imaging during the course of the disease, even before significant clinical changes are detected.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04036084
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Hugues CHABRIAT, MD, PhD
Phone 149952597
Email hugues.chabriat@aphp.fr
Status Recruiting
Phase
Start date August 10, 2019
Completion date January 6, 2023

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Recruiting NCT05755997 - CERebrolysin In CADASIL Phase 2
Recruiting NCT06148051 - AusCADASIL: An Australian Cohort of CADASIL
Recruiting NCT04310098 - CADASIL Registry Study
Completed NCT01114815 - Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) N/A
Recruiting NCT05677880 - Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
Recruiting NCT02795052 - Neurologic Stem Cell Treatment Study N/A
Completed NCT02837354 - The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage? N/A
Recruiting NCT01361763 - Safety Study of Dabigatran in CADASIL Phase 2
Completed NCT02071784 - Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Completed NCT06072118 - Adrenomedullin for CADASIL Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT05473637 - Taiwan Associated Genetic and Nongenetic Small Vessel Disease
Enrolling by invitation NCT02032225 - Generation of a Cellular Model of CADASIL From Skin Fibroblasts N/A
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Active, not recruiting NCT04658823 - Efficacy and Safety of Tocotrienols in CADASIL Phase 2
Withdrawn NCT04334408 - Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Phase 2
Recruiting NCT05734378 - Prognosis of Cerebral Small Vessel Disease
Recruiting NCT05491980 - Florida Cerebrovascular Disease Biorepository and Genomics Center
Completed NCT01865604 - Impact of tDCS on Cerebral Autoregulation N/A